China Resources Pharmaceutical Group Limited (HKG:3320)
Hong Kong
· Delayed Price · Currency is HKD 4.920
-0.030 (-0.61%)
Apr 25, 2025, 4:08 PM HKT
HKG:3320 Revenue
In the year 2024, China Resources Pharmaceutical Group had annual revenue of 257.67B CNY with 5.30% growth. China Resources Pharmaceutical Group had revenue of 129.08B in the half year ending December 31, 2024, with 20.66% growth.
Revenue
257.67B CNY
Revenue Growth
+5.30%
P/S Ratio
0.11
Revenue / Employee
3.54M CNY
Employees
72,700
Market Cap
30.91B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 257.67B | 12.97B | 5.30% |
| Dec 31, 2023 | 244.70B | 26.52B | 12.16% |
| Dec 31, 2022 | 218.18B | -18.62B | -7.86% |
| Dec 31, 2021 | 236.81B | 36.38B | 18.15% |
| Dec 31, 2020 | 200.42B | -4.03B | -1.97% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 31.39B |
| CSPC Pharmaceutical Group | 30.87B |
China Resources Pharmaceutical Group News
- 7 months ago - Health product chain store CR Care to close all 19 branches in Hong Kong in November - Hong Kong Free Press